Loading
NASDAQBasic MaterialsAgricultural Inputs
Latest quote
$1.69
+$0.02 · +1.20%
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Previous close
$1.69
+$0.02 · +1.20%
After-hours
$1.69
$0.00 · 0.00%
Sep 9, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Day range
Current $1.69
52-week range
Current $1.69
Regular session · ET · Market data may be delayed.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Day range
Current $1.69
52-week range
Current $1.69
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 210K USD | 263.45K USD | 394K USD | 438.14K USD |
| Cost of goods sold | — | 177K USD | 76.33K USD | 188.46K USD | 194.15K USD |
| Gross profit | — | 33K USD | 187.11K USD | 205.54K USD | 243.99K USD |
| Research and development | 179K USD | 367K USD | 1.93M USD | 748.79K USD | 500.52K USD |
| Selling, general, and administrative | 5.11M USD | 3.72M USD | 5.56M USD | 5.17M USD | 4.29M USD |
| Operating expenses | 4.23M USD | 4.08M USD | 7.49M USD | 5.92M USD | 4.79M USD |
| Interest income | — | 65K USD | 65.76K USD | — | — |
| Interest expense | 114K USD | 95K USD | 5.36K USD | 8.8K USD | 44.55K USD |
| Depreciation and amortization | 78K USD | 18K USD | 21.16K USD | 54.72K USD | 58.21K USD |
| Operating income | −4.23M USD | −4.05M USD | −7.3M USD | −5.71M USD | −4.54M USD |
| Net income | −4M USD | −5.19M USD | −6.52M USD | −5.74M USD | −4.82M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
